

Supplementary Table 1. List of patients that showed elevated alanine aminotransferase levels during elbasvir/grazoprevir therapy for genotype 1 hepatitis C infection

No.	Age, yr	Sex	Genotype	RNA, IU/L	Liver cirrhosis	GFR, mL/min/1.73 m ²	SVR	Week of ALT flare	ALT (at each week of treatment), IU/L						
									0	2	4	8	12	Post12	Post24
1	74	Female	1	832,154	No	131	Yes	8	15	-	60	85	88	100	-
2	66	Female	1b	904,431	No	165	Yes	2	67	135	55	101	97	39	41
3	64	Female	1b	26,086	No	76	Yes	12	17	-	16	17	136	9	5
4	45	Male	1b	862,909	No	106	Yes	8	34	-	47	84	50	52	34
5	52	Male	1b	526,000	No	93	Yes	8	132	36	43	92	75	25	38
6	54	Male	1b	91,400	No	138	Yes	12	16	-	14	18	91	87	24
7	62	Male	1b	17,900,000	No	97	Yes	12	33	-	56	57	81	56	64
8	77	Female	1b	2,920,000	No	87	FU loss	4	41	-	89	105	71	-	-
9	53	Male	1b	20,900,000	Yes	42	Yes	8	64	-	63	87	218	19	-
10	73	Female	1b	105,840	No	82	Yes	8	132	-	13	89	18	11	-
11	79	Female	1b	2,150,000	No	72	Yes	4	13	-	88	9	9	7	8

GFR, glomerular filtration rate; SVR, sustained virological response; ALT, alanine aminotransferase; FU, follow-up.